Open access
Open access
Powered by Google Translator Translator

Diabetes

RCT | Effect of a comprehensive telehealth intervention vs. telemonitoring and care coordination in patients with persistently poor type 2 diabetes control.

9 Aug, 2022 | 12:44h | UTC

Effect of a Comprehensive Telehealth Intervention vs Telemonitoring and Care Coordination in Patients With Persistently Poor Type 2 Diabetes Control: A Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)

Commentary: Comprehensive telehealth intervention effective for reducing HbA1c in poorly controlled diabetes – Physician’s Weekly

 

Commentary on Twitter

 


Systematic Review | Diabetes mellitus and perioperative outcomes.

9 Aug, 2022 | 12:28h | UTC

Diabetes mellitus and perioperative outcomes: a scoping review of the literature – British Journal of Anaesthesia

 


RCT | Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes.

8 Aug, 2022 | 11:56h | UTC

Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial – Diabetes, Obesity and Metabolism

 


M-A | Effectiveness and safety of new oral and injectable agents for in-hospital management of type 2 diabetes in general wards.

8 Aug, 2022 | 11:37h | UTC

Effectiveness and safety of new oral and injectable agents for in-hospital management of type 2 diabetes in general wards: systematic review and meta-analysis – Diabetes Research and Clinical Practice

 


Cohort study | Adults with Type 2 Diabetes and nonalcoholic fatty liver disease are at increased risk of severe hypoglycemia.

5 Aug, 2022 | 14:30h | UTC

Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease – JAMA Network Open

Commentary: Consider Fatty Liver Disease for Hypoglycemia Risk in Diabetes – JAMA Network Open (free registration required)

 

Commentary on Twitter

 


M-A | GLP1 receptor agonists are associated with increased risk of progression of retinopathy in patients with type 2 diabetes.

2 Aug, 2022 | 12:32h | UTC

Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis – Journal of Diabetes and its Complications (link to abstract – $ for full-text)

Commentary: GLP1 RA use tied to increased risk of rapidly worsening retinopathy in type 2 diabetes – Medical Dialogues

 


RCT | Safety and efficacy of Tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan.

2 Aug, 2022 | 12:05h | UTC

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

See also (note: the dulaglutide dosage used in this trial was probably suboptimal): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

Related:

Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis – Diabetologia

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus.

26 Jul, 2022 | 11:53h | UTC

Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study in Japan – Journal of Diabetes Investigation

 


An approach to the management of diabetes mellitus in cirrhosis: a primer for the hepatologist.

22 Jul, 2022 | 11:26h | UTC

An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist – Journal of Clinical and Experimental Hepatology

 


DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.

21 Jul, 2022 | 13:11h | UTC

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases – Journal of Diabetes and its Complications

 


ADA Guideline Summary | Obesity and weight management for prevention and treatment of Type 2 Diabetes.

12 Jul, 2022 | 13:06h | UTC

Obesity and Weight Management for Prevention and Treatment of Type 2 Diabetes – JAMA (free for a limited period)

Original Guideline: ADA 2022 Standards of Medical Care in Diabetes – American Diabetes Association

 


Post-hoc analysis | Can SGLT2 inhibitors reduce the risk of nephrolithiasis?

7 Jul, 2022 | 12:42h | UTC

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? – The Journal of Clinical Endocrinology & Metabolism

 


Post-hoc analysis | Can SGLT2 inhibitors reduce the risk of hyperuricemia and gout?

7 Jul, 2022 | 12:40h | UTC

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial – European Heart Journal

 


Guideline on the diagnosis and management of peripheral artery disease.

6 Jul, 2022 | 11:42h | UTC

Australian guideline on diagnosis and management of peripheral artery disease: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease – Journal of Foot and Ankle Research

Related:

Australian guideline on management of diabetes-related foot infection: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease – Journal of Foot and Ankle Research

Australian guideline on wound classification of diabetes-related foot ulcers: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease

Australian guideline on wound healing interventions to enhance healing of foot ulcers: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease

Australian guideline on offloading treatment for foot ulcers: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease


Systematic Review | Long-term follow-up on morbidity among women with a history of gestational diabetes mellitus.

6 Jul, 2022 | 11:17h | UTC

Long-term follow-up on morbidity among women with a history of gestational diabetes mellitus: a systematic review – The Journal of Clinical Endocrinology & Metabolism


Delphi-Based Consensus | Practical guidance on basal insulin initiation and titration in Asia.

5 Jul, 2022 | 12:03h | UTC

Practical Guidance on Basal Insulin Initiation and Titration in Asia: A Delphi-Based Consensus – Diabetes Therapy


Stay Updated in Your Specialty

No spam, just news.